Market capitalization | $467.11m |
Enterprise Value | $241.25m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 513.30 |
P/S ratio (TTM) P/S ratio | 993.85 |
P/B ratio (TTM) P/B ratio | 1.48 |
Revenue growth (TTM) Revenue growth | -96.16% |
Revenue (TTM) Revenue | $470.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a PureTech Health Plc - ADR forecast:
3 Analysts have issued a PureTech Health Plc - ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.47 0.47 |
96%
96%
|
|
Gross Profit | -3.20 -3.20 |
-
|
|
EBITDA | -132 -132 |
22%
22%
|
EBIT (Operating Income) EBIT | -136 -136 |
23%
23%
|
Net Profit | -82 -82 |
71%
71%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
PureTech Health Plc is a cross-disciplinary bio-pharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune. It operates through the following segments: Internal, and Affiliates. The Internal segment is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programmes within PureTech's Affiliates division. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
Head office | United Kingdom |
CEO | Bharatt Chowrira |
Founded | 2015 |
Website | puretechhealth.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.